This Element reviews key aspects of RAS biochemistry that are directly relevant to understanding the newly available RAS inhibitors.
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes Königreich
Zustand: New. In English. Artikel-Nr. ria9781009073646_new
Anzahl: Mehr als 20 verfügbar
Anbieter: Kennys Bookstore, Olney, MD, USA
Zustand: New. 2022. 1st Edition. paperback. . . . . . Books ship from the US and Ireland. Artikel-Nr. V9781009073646
Anzahl: Mehr als 20 verfügbar
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Taschenbuch. Zustand: Neu. Neuware - The KRAS oncogene is believed to be the most common single nucleotide variant oncogene in human cancer. Historically, efforts to target KRAS and the other RAS GTPases have struggled. More recently, efforts have focused on identifying and exploiting features unique to specific oncogenic mutations. This has led to the first FDA approval for a RAS targeted therapy. This new agent is a covalent inhibitor that reacts with the cysteine residue created by a codon 12 glycine to cysteine (G12C) mutation within KRAS. Mutant-specific strategies may also exist for other KRAS single nucleotide variants, and recent studies provide examples and mechanisms. Artikel-Nr. 9781009073646
Anzahl: 2 verfügbar
Anbieter: moluna, Greven, Deutschland
Zustand: New. InhaltsverzeichnisIntroduction RAS Biology Oncogenic RAS RAS Targeting Downstream Targeting Upstream Targeting Targeting Specific RAS Mutants KRAS G12C Targeting Direct Targeting of Other RAS Proteins KRAS G12R Pancreatic Cancer. Artikel-Nr. 651387148
Anzahl: Mehr als 20 verfügbar